Head of Immunology, US Medical Affairs: UCB, Inc.
September, 2012: The Stevenson Group has placed the Head of Immunology, US Medical Affairs at UCB, Inc. UCB, a mid-size biopharmaceutical company with global headquarters in Brussels, Belgium, is developing new drugs, both antibody-based and small molecules, designed to treat a range of serious autoimmune diseases. The Head of Immunology, US Medical Affairs will provide scientific and medical leadership to the cross functional Immunology Therapeutic area medical team within US Medical Affairs in order to ensure the successful implementation of the medical portion of the Immunology brand team's plan for its respective products.
Vice President, Regulatory Affairs, R&D: Ikaria, Inc.
September, 2012: The Stevenson Group has placed the Vice President for Regulatory Affairs, R&D at Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients. The Company's lead product INOMAX® (nitric oxide) for inhalation is the only FDA approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. The Vice President for Regulatory Affairs, R&D will develop innovative strategies and approaches towards successful global product registration of first-in-class critical care solutions (pharmaceutical, devices, and drug-device combinations).
Vice President, Clinical/R&D Quality: MedImmune
August, 2012: The Stevenson Group has placed the Vice President, Clinical/R&D Quality at MedImmune, based in Gaithersburg, MD. With one of the largest pipelines in the industry, MedImmune is focused on developing new therapeutic and preventive medicines that hold tremendous potential for patients around the globe in the areas of infectious disease, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease, and neuroscience. The Vice President, Clinical/R&D Quality will lead and set strategic direction for the Clinical/R&D Quality Operations organization and will be accountable for the design, development, execution, and administration of a GxP Quality System meeting all MedImmune and regulatory agency GLP, GCP, and Pilot Plant GMP compliance requirements.
Senior Director, Biomarker and Discovery Research: Immune Tolerance Network
August, 2012: The Stevenson Group has placed the Senior Director, Biomarker and Discovery Research at the Immune Tolerance Network, based in Bethesda, MD. The Immune Tolerance Network (ITN) is a National Institute of Health-funded initiative to facilitate the advancement of immune tolerance-inducing procedures in human clinical practice, towards the development of new and improved treatment and monitoring protocols in kidney, liver and islet transplantation, autoimmune, asthma & allergic diseases. The Senior Director for Biomarker and Discovery Research will play a strategic role in the design and development of biomarker/mechanistic assays and protocols for both ongoing and new clinical trials, as well as oversee multiple collaborations with outside investigators and other networks and consortia, driving demand for ITN’s assays and scientific expertise.
Chief Technology Officer: SAIC-Frederick, Inc.
July, 2012: The Stevenson Group has placed the Chief Technology Officer, SAIC-Frederick, Inc. at the Frederick National Laboratory for Cancer Research, based in Frederick, MD. SAIC-Frederick, a subsidiary of SAIC, is the Operations and Technical Support (OTS) Contractor for the Frederick National Laboratory for Cancer Research, a federally funded research and development center. SAIC-Frederick is one of three Prime NCI contracts at Frederick National Laboratory for Cancer Research and provides state of the art research and development as well as infrastructure support for the entire center. The CTO will provide leadership in advanced technology and basic science programs, and will work with SAIC-Frederick and Frederick National Laboratory for Cancer Research leadership to identify new scientific and technological opportunities which facilitate achievement of NCI's mission.
Portfolio Strategy Lead, Diversified Brands: Merck
July, 2012: The Stevenson Group has placed the Portfolio Strategy Lead, Diversified Brands at Merck, based in Whitehouse Station, NJ. Through the company’s prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, Merck operates in more than 140 countries to deliver innovative health solutions dedicated to putting patients first. The Portfolio Strategy Lead for Diversified Brands will develop and lead portfolio prioritization and portfolio marketing support for Diversified Brands portfolio worldwide.
Senior Medical Director, Translational Medicine: Alexion Pharmaceuticals
June, 2012: The Stevenson Group has placed the Senior Medical Director, Translational Medicine at Alexion Pharmaceuticals, based in Cambridge, MA. Alexion is a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including cancer, hematologic and kidney diseases, transplant, and other inflammatory disorders. The new incumbent will serve as medical lead and clinical expert on early stage project development teams, and contribute to the senior level scientific, strategic, and operational aspects of drug development within translational medicine and early stage development.
Vice President, Global Total Rewards and HR Operations: Aptalis Pharma
May, 2012: The Stevenson Group has placed the Vice President, Global Total Rewards and HR Operations at Aptalis Pharma based in Bridgewater, NJ. Aptalis Pharma is a privately held US-based specialty pharmaceutical company providing innovative, effective therapies for unmet medical needs, including cystic fibrosis and gastrointestinal disorders. The Vice President for Global Total Rewards and HR Operations will be responsible for the overall design, implementation, communication, and administration of progressive compensation programs, policies and procedures which support the Company’s strategic direction.
Bioinformatics Strategy Leader & Manager for Computational Biology & Biostatistics: GE Global Research
May, 2012: The Stevenson Group has placed the Bioinformatics Strategy Leader and Manager for Computational Biology & Biostatistics at GE Global Research based in Niskayuna, NY. GE Global Research is one of the world's most diversified industrial research labs, providing innovative technology for all of GE's businesses. The new incumbent will develop and drive bioinformatics strategy, and lead a team of scientists and engineers within GE's Biosignatures & Signal Processing organization focused on research in computational biology, algorithms for novel biomarker discovery, Biosignatures, and design of next generation molecular diagnostics tests.
Site Head of Manufacturing: EMD Millipore
March, 2012: The Stevenson Group has placed the Site Head of Manufacturing at EMD Millipore, the life sciences division of Merck KGaA, Germany. The Site Head will oversee the worldwide center for bioprocess manufacturing, based in Jaffrey, NH. This site manufactures products that enable pharmaceutical and biotechnology companies to develop clinical and commercial drug materials. The Site Head will lead the strategic operations of the site inclusive of quality, EHS and supply chain initiatives.
Director, Regulatory Affairs: Merrimack Pharmaceuticals
March, 2012: The Stevenson Group has placed the Director of Regulatory Affairs at Merrimack Pharmaceuticals. Based in Cambridge, MA, Merrimack Pharmaceuticals is dedicated to the discovery and development of novel medicines for the treatment of cancer. The company's work is founded on a revolutionary drug discovery platform integrating quantitative data and mathematical models to dissect complex biological systems and direct drug development, allowing the co-development of Rx and Dx. The Director will steer short and long term regulatory strategies across the portfolio and lead interactions with regulatory agencies and the preparation and submission of new applications.
Leader, Global Diagnostics Strategy: GE Global Research
January, 2012: The Stevenson Group has placed the Leader, Global Diagnostics Strategy within the Diagnostics and Biomedical Technologies organization at GE Global Research based in Niskayuna, NY. GE Global Researchis one of the world’s most diversified industrial research labs, providing innovative technology for all of GE’s businesses. The Leader will shape the business direction in high-value diagnostics including the development of a comprehensive R&D strategy incorporating external trends, competitive landscape and inorganic initiatives. Additionally, the Leader will develop strategic collaborations with pharmaceutical and biotechnology companies as well as partner closely with government, external agencies, and academic institutions.
Medical Director, US Medical Affairs - GI/Crohn's Disease: UCB, Inc.
December, 2011: The Stevenson Group has placed the Medical Director, US Medical Affairs – GI/Crohn’s Disease at UCB, Inc. UCB, a mid-size biopharmaceutical company with global headquarters in Brussels, Belgium, is developing new drugs, both antibody-based and small molecules, designed to treat a range of serious autoimmune diseases. The Medical Director will provide the scientific and medical leadership to the cross-functional Immunology Therapeutic area medical team and ensure the successful implementation of the medical portion of the Immunology brand team's plan. Additionally, the Medical Director will serve as a key external interface to clinical investigators and KOLs in the GI scientific and medical community.
Senior Director OD/Talent Management and Senior Director, Communications/HR Project Management: Aptalis Pharma
October, 2011: The Stevenson Group has placed two key HR executives at Aptalis Pharma, based in Bridgewater, NJ. Aptalis Pharma is a privately-held US-based specialty pharmaceutical company providing innovative, effective therapies for unmet medical needs, including cystic fibrosis and gastrointestinal disorders. The Senior Director for Organizational Development and Talent Management will be responsible for designing, implementing and administrating global talent management programs, corporate wide training and career development initiatives. The Senior Director for Communications and HR Project Management will be responsible for creating and implementing global internal communications strategies that support the Vision, Mission, Values and Corporate objectives as well as the Executive Management Team’s messages relative to corporate strategy and direction.
Vice President, NDA Project Leader: Merrimack Pharmaceuticals
October, 2011: The Stevenson Group has placed the Vice President, NDA Project Leader at Merrimack Pharmaceuticals, based in Cambridge, MA. Merrimack Pharmaceuticals is dedicated to the discovery and development of novel medicines for the treatment of cancer. The company's work is founded on a revolutionary drug discovery platform integrating quantitative data and mathematical models to dissect complex biological systems and direct drug development, allowing co-development of Rx and Dx. This highly visible scientific leader role will steer the company's most advanced oncology program as it advances through late stage development and commercialization.
Vice President, Medical: Merrimack Pharmaceuticals
October, 2011: The Stevenson Group has placed the Vice President, Medical at Merrimack Pharmaceuticals. Based in Cambridge, MA Merrimack Pharmaceuticals is dedicated to the discovery and development of novel medicines for the treatment of cancer. The company's work is founded on a revolutionary drug discovery platform integrating quantitative data and mathematical models to dissect complex biological systems and direct drug development, allowing co-development of Rx and Dx. The Vice President, Medical will lead the global clinical strategy for the Company's most advanced oncology program as it advances through late stage development and commercialization.
Director, EMEA Sales & Marketing Effectiveness Analytics: Bausch & Lomb
July, 2011: The Stevenson Group has placed the Director of EMEA, Sales and Marketing Effectiveness Analytics at Bausch & Lomb in Zug, Switzerland. Bausch & Lomb is dedicated to bringing visionary ideas to eye health. Its core businesses include contact lenses and lens care products as well as ophthalmic surgical and pharmaceutical products. The Director will partner with country leadership (Europe, Middle East & Africa) to provide key analytical insight to guide informed business decisions and execute against business needs in the areas of market research, business information, analytics, and promotional effectiveness.
Senior Director, Orphan and Genetic Diseases, External R&D Innovation: Pfizer, Inc.
July, 2011: The Stevenson Group has placed the Senior Director of Orphan and Genetic Diseases in the External R&D Innovation organization at Pfizer, Inc., the world’s largest research-based biopharmaceutical company. The Senior Director, Orphan and Genetic Diseases Research Unit will be responsible for defining and implementing the R&D stage programs and support the build-up and delivery of the portfolio via global scouting, assessment and integration of external opportunities.
Medical Director, MM-121: Merrimack Pharmaceuticals
July, 2011: The Stevenson Group has placed the Medical Director, MM-121 at Merrimack Pharmaceuticals. Based in Cambridge, MA, Merrimack Pharmaceuticals is dedicated to the discovery and development of novel medicines for the treatment of cancer. The company’s work is founded on a revolutionary drug discovery platform integrating quantitative data and mathematical models to dissect complex biological systems and direct drug development, allowing co-development of Rx and Dx. The Medical Director will lead the development of Merrimack's flagship oncology program MM-121, in collaboration with Sanofi. Merrimack is testing MM-121 in combination with both chemotherapies and other targeted agents across a wide spectrum of solid tumors, including lung, breast and ovarian cancers.
Senior Vice President of Operations: iCyt Mission Technology, Inc.
June, 2011: The Stevenson Group has placed the Senior Vice President of Operations at iCyt Mission Technology, Inc., a subsidiary of Sony Corporation of America. iCyt manufactures and delivers flow cytometry instrument products to different markets around the world. The Senior Vice President of Operations will be responsible for day-to-day management and operations of all product manufacture, service, technical support, IT, and global product distribution activities.
Chief Executive Officer: SAIC-Frederick, Inc.
May, 2011: The Stevenson Group has placed the Chief Executive Officer at SAIC-Frederick, Inc., based in Frederick, MD. SAIC-Frederick is a wholly-owned subsidiary of Science Applications International Corporation (SAIC) and operates exclusively under a single, long-term contract to the National Cancer Institute (NCI), part of the U.S. National Institutes of Health. The CEO will be responsible for overseeing all operations and technical support contract activities as well as leading scientific, research, and administrative operations, in close partnership with the NCI to ensure achievement of strategic plans and objectives.
Operations and Site Engineering Leadership: EMD Millipore
April, 2011: The Stevenson Group has placed three key manufacturing operations leaders at EMD Millipore, the life sciences division of Merck KGaA, Germany. The Site Operations Managers (2) will be responsible for day-to-day and strategic operations of the Jaffrey, NH site, the worldwide center for bioprocess manufacturing for the company. The Site Engineering Manager will oversee all aspects of plant engineering within the site and lead all engineering of both filtration device and membrane centers, while developing and leading strategic facility initiatives.
Head of Inflammation and Immunology and Head of CV/Metabolics, External R&D Innovation: Pfizer, Inc.
December, 2011: The Stevenson Group has placed the Head of Inflammation and Immunology, and the Head of CV/Metabolics in the External R&D Innovation (ERDI) group at Pfizer, Inc., the world’s largest research-based biopharmaceutical company. The Head of these respective R&D units will be responsible for defining and implementing the R&D stage programs and support the build-up and delivery of the portfolio via global scouting, assessment and integration of external opportunities.
Head of Pricing and Business Operations: GE Healthcare
November, 2010: The Stevenson Group has placed the Head of Pricing and Business Operations at GE Healthcare, Medical Diagnostics division, based in Princeton, NJ. GE Healthcare's expertise in medical imaging, medical diagnostics, patient monitoring and disease research is enhancing patient care by enabling healthcare providers to better diagnose and treat serious diseases. The Head of Pricing and Business Operations will lead all commercial and government operations pertaining to GE Healthcare, Medical Diagnostics in the US, Canada, and Latin America as well as drive sales operations processes and strategic pricing initiatives.
Senior Medical Director: Merrimack Pharmaceuticals
November, 2010: The Stevenson Group has placed the Senior Medical Director at Merrimack Pharmaceuticals. Based in Cambridge, MA, Merrimack Pharmaceuticals is dedicated to the discovery and development of novel medicines for the treatment of cancer. The company's work is founded on a revolutionary drug discovery platform integrating quantitative data and mathematical models to dissect complex biological systems and direct drug development, allowing co-development of Rx and Dx. In this clinical leadership role, the new incumbent will advance the company’s robust pipeline of system biology driven oncology programs.
Vice President/General Manager: Rhodes Pharmaceuticals
November, 2010: The Stevenson Group has placed the Vice President & General Manager at Rhodes Pharmaceuticals, based in Coventry, RI. Rhodes Pharmaceuticals is a specialty pharmaceutical company established to compete in the generic pharmaceutical market. The Vice President & General Manager will be responsible for developing a portfolio of generic and specialty pharmaceutical products while leading strategic activities across commercial, product, intellectual property, technical operations, financial planning, and regulatory affairs.
Senior Customer Segment Manager(s), Market Strategies: Purdue Pharma
August, 2010: The Stevenson Group has placed two Senior Customer Segment Managers at Purdue Pharma, based in Stamford, CT. The Customer Segment Managers, Market Strategies will advance the development and implementation of market segment and customer-focused plans and objectives related to assigned customer segments and accounts. Additionally, the individuals will access and apply high value market research and data resources that support market and customer analyses, including the identification of major customers within markets. Purdue Pharma is a privately held pharmaceutical company and an industry leader in pain medication research and development.
Senior Director, Preclinical Operations: Regeneron Pharmaceuticals
June, 2010: The Stevenson Group has placed the Senior Director, Preclinical Operations at Regeneron Pharmaceuticals, based in Tarrytown, NY. Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in disease areas such as ophthalmology, inflammation, cancer, and hypercholesterolemia. The Senior Director will manage preclinical development operations across all company programs and establish a sustainable project and program management infrastructure for the department, accountable for timelines, budgeting and resource allocation.
Executive Director, Clinical Development Laboratory Head, Early Development: Merck
June, 2010: The Stevenson Group has placed the Executive Director, Clinical Development Laboratory Head within the Early Development Group at Merck, based in Rahway, NJ. Through the company’s prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, Merck operates in more than 140 countries to deliver innovative health solutions dedicated to putting patients first. The Executive Director, Clinical Development Laboratory directs the laboratories providing Biomarker/Bio-analytical strategy, validation and support to Merck R&D, including Clinical Pharmacology, Experimental Medicine and Therapeutic Franchises.
Director, Project Management: SAIC-Frederick, Inc.
May, 2010: The Stevenson Group has placed the Director of Project Management in the Applied and Developmental Directorate of SAIC-Frederick, Inc. at the NCI-Frederick in Rockville, MD. SAIC-Frederick, Inc. is a wholly-owned subsidiary of Science Applications International Corporation (SAIC) and operates exclusively under a single, long-term contract to the National Cancer Institute (NCI), part of the U.S. National Institutes of Health. The Applied and Developmental Directorate within SAIC-Frederick is comprised ofthe Clinical Services Program and the Developmental Therapeutics Program Support Group, both of which support the clinical trials and drug development efforts at NCI and NIAID. The Director will lead the direction, planning, and execution of a Project Management Office (PMO) that supports the National Cancer Institute’s Experimental Therapeutics program (NExT).
Medical Director(s): Reata Pharmaceuticals
April, 2010: The Stevenson Group has placed two Medical Directors at Reata Pharmaceuticals, headquartered in Irving, TX. Reata is a biotechnology company developing a portfolio of antioxidant inflammation modulators (AIMs) and protein folding modulators for a variety of inflammation-related diseases. The Medical Directors will be responsible for providing clinical development expertise, management, and leadership for late stage development activities on the company’s lead program targeting Chronic Kidney Disease (CKD).
Senior Director, Corporate Manufacturing Support: MedImmune
April, 2010: The Stevenson Group has placed the Senior Director, Corporate Manufacturing Support at MedImmune, based in Gaithersburg, MD. With one of the largest pipelines in the industry, MedImmune is focused on developing new therapeutic and preventive medicines that hold tremendous potential for patients around the globe in the areas of infectious disease, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease, and neuroscience. The Senior Director, Corporate Manufacturing Support will provide high-level scientific as well as technical expertise to the Operations function, and will ensure the quality of work within MedImmune by directing policies and partnering with the manufacturing sites across the company.
Senior Director, Regulatory Affairs and Quality: Merrimack Pharmaceuticals
March, 2010: The Stevenson Group has placed the Senior Director, Regulatory Affairs and Quality at Merrimack Pharmaceuticals based in Cambridge, MA. Merrimack Pharmaceuticals is dedicated to the discovery and development of novel medicines for the treatment of cancer. The company’s work is founded on a revolutionary drug discovery platform integrating quantitative data and mathematical models to dissect complex biological systems and direct drug development, allowing co-development of Rx and Dx. The new incumbent will be charged with enhancing and establishing the company’s regulatory and quality infrastructure, serving as a key interface with global regulatory agencies, and driving regulatory strategy for a robust pipeline of early and mid-stage oncology programs.
Senior Vice President, Civilian Health Operations: SAIC Health Solutions
January, 2010: The Stevenson Group has placed the Senior Vice President, Civilian Health Operations at SAIC Health Solutions Business Unit, headquartered in McLean, VA. The SVP will lead SAIC's civilian health team, manage the operation's long-term growth strategy, and develop new solutions to meet the evolving business needs of SAIC's civilian, public health, and life sciences customers. As part of SAIC's Health Solutions Business Unit, the Civilian Health Operation provides solutions to local, state, federal, and commercial health organizations to prevent, prepare for, detect, and respond to public health threats. It also supports biomedical research and the advancement of life sciences in the healthcare market.
Vice President, Sales and Marketing: Rhodes Pharmaceuticals
September, 2009: The Stevenson Group has placed the Vice President, Sales and Marketing at Rhodes Pharmaceuticals in Coventry, RI. Rhodes Pharmaceuticals is a specialty pharmaceutical company established to compete in the generic pharmaceutical market. The new Vice President of Sales and Marketing will develop and lead commercial opportunities inclusive of delivering and executing marketing and sales strategies and launching new generic products while ensuring competitive penetration into the appropriate distribution channels and networks.
Division Manager, Bioprocess Business - Mexico: Millipore Corporation
August, 2009: The Stevenson Group has placed the Division Manager, Bioprocess - Mexico at Millipore Corporation. As a Division Manager, BioProcess – Mexico, the leader will be charged with steering the commercial activities for the company's emerging bioprocess business and reinforcing their strong positioning in the local region. The Bioprocess Division partners and supports pharmaceutical and biotechnology companies to optimize their manufacturing productivity, ensure the quality of drugs, and scale up the production of difficult-to-manufacture biologics.
Global Director, Scientific Affairs, Respiratory Disease Area: Merck
August, 2009: The Stevenson Group has placed the Global Director for Scientific Affairs, Respiratory Disease Area at Merck. Through the company’s prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, Merck operates in more than 140 countries to deliver innovative health solutions dedicated to putting patients first. The leader will be responsible for scientific leadership within the Respiratory Disease area. The incumbent will lead efforts on behalf of the Respiratory Disease Area to maximize meaningful scientific exchange externally, and incorporating voice of customer input to internally impact how Merck discovers, develops and commercializes new drugs and vaccines.
Senior Vice President/Business Unit General Manager: SAIC Health Solutions
August, 2009: The Stevenson Group has placed the Senior Vice President and Business Unit General Manager at SAIC Health Solutions Business Unit (HSBU). SAIC's HSBU provides information technology, public health, biomedical support and health services and solutions. The Senior Vice President/Business Unit General Manager will be responsible for developing and managing SAIC's work for federal government and commercial health customers, including the Departments of Defense, Health and Human Services, and Veteran Affairs.
Vice President, Clinical Operations: Quark Pharmaceuticals
June, 2009: The Stevenson Group has placed the Vice President, Clinical Operations at Quark Pharmaceuticals, based in its US headquarters in Fremont, CA. Quark is an emerging pharmaceutical company developing new drugs based on the discoveries of novel targets and therapeutic concepts, including its innovative technology platform for identification of novel functional target genes and proteins, the "BiFAR" technology. The new incumbent will be responsible for providing global leadership within the Clinical Operations organization as well as for setting direction, implementation, and monitoring of all clinical studies across Europe, US, India, and Israel.
Vice President, Medical Health Technology: Sony Corporation of America
May, 2009: The Stevenson Group has placed the Vice President, Medical Health Technology at Sony Corporation of America based in New York, NY. Sony is a leading provider of innovative medical products and devices designed for a wide range of medical applications as stand-alone hardware or for incorporation into integrated medical systems. The Vice President of Medical and Health Technology Business Development will be responsible for helping Sony leverage existing capabilities and marry them to new business opportunities within the medical diagnostics and devices marketplace.
Director of IT/Quality Control: Covance, Inc.
May, 2009: The Stevenson Group has placed the Director of IT/Quality Control for Covance, Inc. Covance is one of the world’s largest and most comprehensive drug development services companies with offices in 60 countries. Through its nonclinical, clinical, and commercialization services, Covance has helped pharmaceutical and biotech companies develop one-third of all prescription medicines in the market today. The new incumbent will be responsible for developing the strategy and executing all quality and validation activities for the Company’s global applications as they are implemented in the Covance environment.
Executive Director, Medical Communications: Merck
April, 2009: The Stevenson Group has placed the Executive Director, Medical Communications at Merck in Upper Gwynedd, PA. Through the company’s prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, Merck operates in more than 140 countries to deliver innovative health solutions dedicated to putting patients first. The Executive Director, Medical Communications will be responsible for developing an integrated franchise publication strategy as well as establishing, maintaining, and fostering relationships with External Scientific and Editorial leaders.
Senior Director(s)/Director(s), Clinical Development: MedImmune
January, 2009: The Stevenson Group has placed four key clinical development leaders at MedImmune based in Gaithersburg, MD. The two Senior Directors of Clinical Development in the areas of Inflammation and Rheumatology, a Director of Clinical Development, Inflammation, and a Medical Director of Vaccine Development will lead clinical development efforts in their respective therapeutic area of expertise. With one of the largest pipelines in the industry, MedImmune is focused on developing new therapeutic and preventive medicines that hold tremendous potential for patients around the globe in the areas of infectious disease, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease, and neuroscience.